A Filip1, A Pinzano2, A Bianchi3, B Fève4, S Jalkanen5, P Gillet6, D Mainard7, P Lacolley8, J Magdalou9, N Mercier10. 1. UMR S_ 1116 Université de Lorraine-INSERM, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France. Electronic address: Filip-Anna@wp.pl. 2. UMR 7365 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France. Electronic address: astrid.pinzano@univ-lorraine.fr. 3. UMR 7365 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France. Electronic address: arnaud.bianchi@univ-lorraine.fr. 4. Centre de Recherche Saint-Antoine INSERM-Université Paris 6, UMR S_938, Paris, France; Institut Hospitalo-Universitaire ICAN, Paris, France; Assistance-Publique des Hôpitaux de Paris, Hôpital Saint-Antoine, Service d'Endocrinologie, Paris, France. Electronic address: bfeve@free.fr. 5. MediCity Research Laboratory, University of Turku, Turku, Finland. Electronic address: sirjal@utu.fi. 6. UMR 7365 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Centre Hospitalo-Universitaire, Nancy, France. Electronic address: Pierre.Gillet@univ-lorraine.fr. 7. UMR 7365 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Centre Hospitalo-Universitaire, Nancy, France. Electronic address: didier.mainard@univ-lorraine.fr. 8. UMR S_ 1116 Université de Lorraine-INSERM, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Centre Hospitalo-Universitaire, Nancy, France. Electronic address: patrick.lacolley@inserm.fr. 9. UMR 7365 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France; Centre Hospitalo-Universitaire, Nancy, France. Electronic address: jacques.magdalou@univ-lorraine.fr. 10. UMR S_ 1116 Université de Lorraine-INSERM, Vandœuvre-lès-Nancy, France; Fédération de Recherche 3209 Université de Lorraine-CNRS, Vandœuvre-lès-Nancy, France. Electronic address: nathalie.mercier@univ-lorraine.fr.
Abstract
OBJECTIVE: Semicarbazide-sensitive amine oxidase (SSAO) catalyzes the oxidation of primary amines into ammonia and reactive species (hydrogen peroxide, aldehydes). It is highly expressed in mammalian tissues, especially in vascular smooth muscle cells and adipocytes, where it plays a role in cell differentiation and glucose transport. The study aims at characterizing the expression and the activity of SSAO in rat and human articular cartilage of the knee, and to investigate its potential role in chondrocyte terminal differentiation. DESIGN: SSAO expression was examined by immunohistochemistry and western blot. Enzyme activity was measured using radiolabeled benzylamine as a substrate. Primary cell cultures of rat chondrocytes were treated for 21 days by a specific SSAO inhibitor, LJP 1586. Terminal chondrocyte differentiation markers were quantified by RT-qPCR. The basal and IL1β-stimulated glucose transport was monitored by the entrance of (3)[H]2-deoxyglucose in chondrocytes. RESULTS: SSAO was expressed in chondrocytes of rat and human articular cartilage. SSAO expression was significantly enhanced during the hypertrophic differentiation of chondrocytes characterized by an increase in MMP13 and in alkaline phosphatase (ALP) expressions. SSAO inhibition delayed the late stage of chondrocyte differentiation without cell survival alteration and diminished the basal and IL1β-stimulated glucose transport. Interestingly, SSAO activity was strongly increased in human osteoarthritic cartilage. CONCLUSIONS: SSAO was expressed as an active form in rat and human cartilage. The results suggest the involvement of SSAO in rat chondrocyte terminal differentiation via a modulation of the glucose transport. In man, the increased SSAO activity detected in osteoarthritic patients may trigger hypertrophy and cartilage degeneration.
OBJECTIVE:Semicarbazide-sensitive amine oxidase (SSAO) catalyzes the oxidation of primary amines into ammonia and reactive species (hydrogen peroxide, aldehydes). It is highly expressed in mammalian tissues, especially in vascular smooth muscle cells and adipocytes, where it plays a role in cell differentiation and glucose transport. The study aims at characterizing the expression and the activity of SSAO in rat and humanarticular cartilage of the knee, and to investigate its potential role in chondrocyte terminal differentiation. DESIGN:SSAO expression was examined by immunohistochemistry and western blot. Enzyme activity was measured using radiolabeled benzylamine as a substrate. Primary cell cultures of rat chondrocytes were treated for 21 days by a specific SSAO inhibitor, LJP 1586. Terminal chondrocyte differentiation markers were quantified by RT-qPCR. The basal and IL1β-stimulated glucose transport was monitored by the entrance of (3)[H]2-deoxyglucose in chondrocytes. RESULTS:SSAO was expressed in chondrocytes of rat and humanarticular cartilage. SSAO expression was significantly enhanced during the hypertrophic differentiation of chondrocytes characterized by an increase in MMP13 and in alkaline phosphatase (ALP) expressions. SSAO inhibition delayed the late stage of chondrocyte differentiation without cell survival alteration and diminished the basal and IL1β-stimulated glucose transport. Interestingly, SSAO activity was strongly increased in humanosteoarthritic cartilage. CONCLUSIONS:SSAO was expressed as an active form in rat and humancartilage. The results suggest the involvement of SSAO in rat chondrocyte terminal differentiation via a modulation of the glucose transport. In man, the increased SSAO activity detected in osteoarthritic patients may trigger hypertrophy and cartilage degeneration.
Authors: Anna Filip; Soraya Taleb; Rümeyza Bascetin; Mohammad Jahangiri; Matthieu Bardin; Cindy Lerognon; Bruno Fève; Patrick Lacolley; Sirpa Jalkanen; Nathalie Mercier Journal: Front Cardiovasc Med Date: 2022-09-13
Authors: Nathalie Mercier; Sven-Christian Pawelzik; John Pirault; Miguel Carracedo; Oscar Persson; Bastien Wollensack; Anders Franco-Cereceda; Magnus Bäck Journal: Oxid Med Cell Longev Date: 2020-01-14 Impact factor: 6.543